In the realm of immunological research, the study of central nervous system (CNS) pathways relies heavily on well-characterized animal models. One of the most significant tools for this purpose is the eae mog peptide. As someone who follows the latest developments in biochemical research materials, I have observed how these specific sequences, particularly the MOG35-55 variant, have become foundational for researchers investigating complex autoimmune processes.
The Significance of MOG35-55 in Research
The MOG peptide is derived from the Myelin Oligodendrocyte Glycoprotein, a structural protein found in the myelin sheath. When discussing EAE, which stands for Experimental Autoimmune Encephalomyelitis, the MOG-induced EAE model is widely regarded as the gold standard for studying demyelinating conditions in a controlled laboratory setting.
The specific fragment, myelin oligodendrocyte glycoprotein (MOG 35-55), is frequently utilized because it consistently triggers a reproducible immune response. Whether you are sourcing a 25 mg vial or an Experimental Autoimmune Encephalomyelitis kit (EAE) with MOG35-55 peptide, the purity and sequence accuracy—typically MEVGWYRSPFSRVVHLYRNGK—are paramount to the integrity of the study.
Mechanisms of Induction
When investigating how EAE was evaluated by peptide immunization, researchers often focus on the interplay between the antigen and the host's immune system. It is well-documented that the MOG peptide can induce typical EAE, which often presents with ascending paralysis in murine subjects.
A common procedural detail involves the use of adjuvants. In many protocols, MOG peptides and CFA were injected into mice to facilitate the necessary immune priming. The amount of Complete Freund’s Adjuvant (CFA) is a critical variable that researchers must calibrate to ensure the induction is consistent. Furthermore, studies have shown that EAE induction with MOG peptide is distinct from model EAE induction using MOG35–55: impact of CFA amount s using whole proteins, as the pep Active induction of experimental autoimmune tide-specific approach allows for more granular control over T-cell and B-cell epitope targeting.
Emerging Trends and Variations
Beyond the standard 35-55 sequence, other variants exist to address different research objectives:
* Human (hu)-MOG1–125 induced EAE: This involves a longer sequence and is often compared against the shorter peptide to study B-cell recognition of native proteins.
* OM-MOG: Recent literature suggests that OM-MOG treats MOG-EAE in a peptide-specific manner, highligh What is EAE (Experimental Autoimmune Encephalomyelitis)? ting the potential for using modified peptid by A Dagkonaki·2020·Cited by 29—The results show thatOM-MOG treats MOG-EAE in a peptide-specific manner Both MOG peptides induced EAE, but only mice receiving two immunizations of 200μg MOG Read more es to modulate es Myelin Oligodendrocyte Glycoprotein (MOG 35-55), 25 mg tablished immune responses.
* MOGtag: This family of fusion proteins offers additional versatility for those looking t Human (MOG 1-125) and (MOG-35-55) Myelin o expand beyond simple peptide immunization.
Considerations for Model Reliability
When selecting EAE model induction peptides, it is essential to consider the source and the validated activity of the material. Reliable suppliers ensure that the by AE Wright·2024·Cited by 2—MOG peptides and CFA were injected into miceto induce experimental autoimmune encephalomyelitis (MOG-EAE), followed by intervention with PLGA Read more MOG35-55, a peptide derived from the Myelin Oligodendrocyte Glycoprotein, is synthesized with high-performance liquid chromatography (HPLC) verification.
In my view, the success of any Experimental Autoimmune Encephalomyelitis (EAE) study depends on the precision of the peptides used. Whether the study involves active immunization or the monitoring of CD4+ and CD8+ T-cell responses, the use of a standardized MOG35-55 peptide ensures that data remains comparable across different laboratories.
As the scientific community continues to refine these models, the focus remains on the specific epitope interactions that define these complex pathways. By maintaining strict protocols and using high-quality reagents, researchers can continue to advance our understanding of how these proteins influence the CNS environment.